Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lessened its stake in Inari Medical, Inc. (NASDAQ:NARI) by 58.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 496 shares of the company’s stock after selling 693 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Inari Medical were worth $32,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Bamco Inc. NY grew its holdings in Inari Medical by 18.2% during the 3rd quarter. Bamco Inc. NY now owns 557,937 shares of the company’s stock valued at $36,489,000 after purchasing an additional 86,000 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Inari Medical during the third quarter worth about $2,564,000. Fiera Capital Corp lifted its stake in shares of Inari Medical by 63.4% in the third quarter. Fiera Capital Corp now owns 560,756 shares of the company’s stock worth $36,673,000 after acquiring an additional 217,606 shares in the last quarter. Asset Management One Co. Ltd. boosted its holdings in Inari Medical by 19.5% in the third quarter. Asset Management One Co. Ltd. now owns 47,390 shares of the company’s stock valued at $3,099,000 after purchasing an additional 7,720 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in Inari Medical by 37.0% during the 3rd quarter. New York State Common Retirement Fund now owns 281,427 shares of the company’s stock valued at $18,405,000 after purchasing an additional 76,072 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Insider Buying and Selling

In other Inari Medical news, CFO Mitch C. Hill sold 6,000 shares of the stock in a transaction on Friday, April 12th. The stock was sold at an average price of $40.96, for a total value of $245,760.00. Following the sale, the chief financial officer now directly owns 181,294 shares of the company’s stock, valued at $7,425,802.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Inari Medical news, Director William Hoffman sold 1,451 shares of the company’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $40.00, for a total value of $58,040.00. Following the completion of the transaction, the director now owns 999,782 shares in the company, valued at approximately $39,991,280. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Mitch C. Hill sold 6,000 shares of the firm’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $40.96, for a total transaction of $245,760.00. Following the completion of the sale, the chief financial officer now owns 181,294 shares in the company, valued at approximately $7,425,802.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,451 shares of company stock valued at $1,949,000. Insiders own 10.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on NARI. Needham & Company LLC reiterated a “buy” rating and set a $72.00 target price on shares of Inari Medical in a research note on Wednesday, March 6th. Piper Sandler downgraded shares of Inari Medical from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $85.00 to $55.00 in a research note on Thursday, February 29th. Truist Financial dropped their target price on shares of Inari Medical from $61.00 to $52.00 and set a “hold” rating for the company in a research report on Friday, March 22nd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $75.00 price target on shares of Inari Medical in a research report on Friday, April 12th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $73.71.

Inari Medical Stock Performance

Shares of NASDAQ:NARI opened at $37.93 on Tuesday. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $71.85. The company’s fifty day moving average is $46.48 and its two-hundred day moving average is $54.98. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -1,264.33 and a beta of 0.84.

Inari Medical (NASDAQ:NARI) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.09). Inari Medical had a positive return on equity of 1.23% and a negative net margin of 0.33%. The business had revenue of $132.10 million for the quarter, compared to analyst estimates of $131.82 million. During the same quarter last year, the company earned ($0.11) EPS. Inari Medical’s revenue was up 22.5% compared to the same quarter last year. Sell-side analysts expect that Inari Medical, Inc. will post -0.39 EPS for the current fiscal year.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.